Find Academic Supervisors

Molly ThomasView profile

Assistant Professor

• Inflammatory bowel disease
• Gastroenterology
• Immunology
• +6 more

Molly Thomas is an inflammatory bowel disease specialist and physician-scientist at Oregon Health & Science University School of Medicine, Department of Medicine. She is board-certified in Internal Medicine and Gastroenterology, specializing in Crohn's disease, ulcerative colitis, microscopic colitis, celiac disease, and inflammatory gastrointestinal complications related to cancer immunotherapy. Her educational background includes: B.S. from Stanford University Ph.D. from University of California, San Francisco M.D. from University of California, San Francisco Internal Medicine Residency at Massachusetts General Hospital Gastroenterology Fellowship at Massachusetts General Hospital Dr. Thomas's research focuses on immunology and inflammatory responses in gastrointestinal diseases, with particular emphasis on the intersection between cancer immunotherapy and gastrointestinal complications. Her work combines clinical care with translational research, investigating how patient experiences can inform scientific understanding of inflammatory gastrointestinal diseases. She has published extensively on immune checkpoint inhibitor complications, inflammatory bowel disease mechanisms, and immune responses in conditions like COVID-19. Her research demonstrates a clear trend toward increasingly sophisticated immune profiling techniques, moving from basic immunological studies to single-cell transcriptomic analyses of tissue samples. Her work spans multiple disciplines including gastroenterology, immunology, oncology, and infectious disease, reflecting the interdisciplinary nature of modern medical research. Dr. Thomas is an active member of several professional organizations: American Gastroenterological Association American Association for the Study of Liver Diseases Society for Immunotherapy of Cancer As a physician-scientist, she maintains a dual role as a longitudinal care provider building long-term relationships with patients, an advocate supporting patients in understanding their diseases, and a researcher inspired by clinical observations to improve care for individuals with inflammatory gastrointestinal conditions. Her collaborative approach is evident in her numerous multi-institutional research projects, particularly with Massachusetts General Hospital researchers.

• Gastroenterology
• Hepatology
• Bile Acid Diarrhea
• +4 more

Lars Kristian Munck is a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen, specializing in Internal Medicine with a focus on Gastroenterology and Hepatology. Based at Lykkebækvej 1, 4600 Køge, Denmark, he maintains dual academic-clinical affiliations through the University of Copenhagen and Region Sjælland healthcare system. Dr. Munck's research program centers on gastrointestinal disorders, particularly bile acid metabolism abnormalities and inflammatory bowel conditions. His work spans diagnostic methodology development, clinical trial design, and epidemiological analysis of long-term outcomes. Key research themes include bile acid diarrhea pathophysiology and treatment, microscopic colitis progression, and the relationship between gastrointestinal disorders and cancer risk. His methodological expertise includes designing prospective cohort studies, randomized controlled trials, and diagnostic test comparisons. Analysis of Dr. Munck's publication record reveals a consistent focus on clinically relevant gastrointestinal research with immediate patient care applications. His work demonstrates particular strength in designing and executing large-scale clinical studies, including the European Microscopic Colitis Group cohort and Danish nationwide registry studies. Recent publications show increasing attention to diagnostic accuracy and treatment personalization in complex gastrointestinal conditions. Dr. Munck maintains extensive European collaborations, particularly through the European Microscopic Colitis Group [EMCG]. His research has gained significant traction in the medical community, with multiple publications referenced in clinical guidelines and disseminated through academic platforms, social media channels, and news outlets. His work on colesevelam for bile acid diarrhea treatment published in The Lancet Gastroenterology and Hepatology has received substantial citation attention with 41 Scopus citations.